Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Drugs with high plasma protein binding have:

Lower volumes of distribution. **Explanation:** The correct answer is **C. Lower volumes of distribution**. **1. Why the correct answer is right:** Volume of distribution ($V_d$) is a theoretical volume that relates the amount of drug in the body to its concentration in the plasma. Drugs with **high plasma protein binding** (primarily to albumin or $\alpha_1$-acid glycoprotein) are effectively "trapped" within the vascular compartment. Because only the free (unbound) fraction of a drug can cross capillary membranes to enter the tissues, highly bound drugs remain in the plasma, resulting in a high plasma concentration and a mathematically **low $V_d$**. **2. Why the incorrect options are wrong:** * **A. Short duration of action:** Generally, protein binding acts as a "reservoir." As free drug is metabolized or excreted, bound drug dissociates to maintain equilibrium. This typically **prolongs** the duration of action, not shortens it. * **B. Less drug interactions:** Highly protein-bound drugs are prone to **displacement interactions**. If a second drug with higher affinity is introduced, it can displace the first drug, leading to a sudden increase in the free (active) fraction, potentially causing toxicity (e.g., Warfarin displaced by Sulfonamides). **3. NEET-PG High-Yield Pearls:** * **Acidic drugs** (e.g., NSAIDs, Warfarin, Phenytoin) bind primarily to **Albumin**. * **Basic drugs** (e.g., Lidocaine, Propranolol) bind primarily to **$\alpha_1$-acid glycoprotein**. * **Dialysis Utility:** Drugs with high protein binding (and high $V_d$) are **not** easily removed by hemodialysis because they are not free in the plasma to be filtered. * **Formula:** $V_d = \frac{\text{Total amount of drug in body}}{\text{Plasma concentration}}$. High binding = High plasma concentration = Low $V_d$.

Q: Which of the following inhibits theophylline metabolism?

Ciprofloxacin. **Explanation:** The correct answer is **Ciprofloxacin**. This question tests your knowledge of **Cytochrome P450 (CYP) enzyme interactions**, a high-yield topic for NEET-PG. **Why Ciprofloxacin is correct:** Theophylline is primarily metabolized by the hepatic enzyme **CYP1A2**. Ciprofloxacin is a potent **inhibitor** of CYP1A2. When co-administered, Ciprofloxacin reduces the clearance of theophylline, leading to increased serum levels and a high risk of toxicity (e.g., seizures, arrhythmias). This is a classic clinical contraindication. **Analysis of Incorrect Options:** * **Griseofulvin:** This is a known **Enzyme Inducer**. It would increase the metabolism of drugs like warfarin or oral contraceptives, rather than inhibiting them. * **Prednisolone:** Glucocorticoids generally do not have a significant inhibitory effect on theophylline metabolism. In fact, theophylline and steroids are often used together in asthma management without major metabolic interference. * **Isoniazid (INH):** While INH is a CYP inhibitor (notably CYP2C19 and CYP3A4), it is not the primary inhibitor associated with theophylline. Ciprofloxacin is the much more potent and clinically significant inhibitor for the CYP1A2 pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Theophylline Inhibitors (Mnemonic: VITAMINS C):** **V**erapamil, **I**soniazid (weak), **T**roleandomycin, **A**miodarone, **M**acrolides (Erythromycin), **I**nterferon, **N**avane, **S**imetidine (Cimetidine), and **Ciprofloxacin**. * **Theophylline Inducers:** Smoking (tobacco/marijuana), Phenytoin, Rifampicin, and Phenobarbitone. * **Therapeutic Range:** Theophylline has a narrow therapeutic index (10–20 µg/mL). Monitoring is essential when adding a CYP1A2 inhibitor.

Q: The maximum effect of a drug is defined by which of the following parameters?

Efficacy. ### Explanation **Correct Option: C. Efficacy** In pharmacodynamics, **Efficacy** (or intrinsic activity) refers to the maximum response ($E_{max}$) achievable by a drug, regardless of the dose. It is determined by the drug's ability to activate a receptor once bound. On a graded Dose-Response Curve (DRC), efficacy is represented by the **height (plateau)** of the curve. Clinical effectiveness is more dependent on efficacy than on potency. **Analysis of Incorrect Options:** * **A. Therapeutic Index (TI):** This is a measure of drug **safety**, calculated as the ratio of the Median Lethal Dose ($LD_{50}$) to the Median Effective Dose ($ED_{50}$). A higher TI indicates a safer drug. * **B. Potency:** This refers to the **amount (dose)** of a drug required to produce an effect of a given intensity (usually $EC_{50}$). On a DRC, potency is represented by the **position along the x-axis** (leftward shift indicates higher potency). A more potent drug simply requires a smaller dose to achieve the same effect; it does not necessarily have a higher maximum effect. * **D. Adversity:** This is a general term relating to adverse drug reactions (ADRs) or toxicity and does not define the therapeutic maximum effect. **High-Yield Clinical Pearls for NEET-PG:** * **Efficacy vs. Potency:** If Drug A produces a 100% response at 10mg and Drug B produces a 50% response at 2mg, Drug A is **more efficacious**, while Drug B is **more potent**. * **Full Agonists** have an intrinsic activity of 1 (maximum efficacy). * **Antagonists** have an intrinsic activity of 0 (they bind but produce no response). * **Partial Agonists** have an intrinsic activity between 0 and 1; they can act as "functional antagonists" in the presence of a full agonist.

Q: What does the ratio of LD50 to ED50 represent?

Therapeutic index. **Explanation:** The ratio of **LD50 (Lethal Dose in 50% of subjects)** to **ED50 (Effective Dose in 50% of subjects)** defines the **Therapeutic Index (TI)**. Mathematically, **TI = LD50 / ED50**. This parameter serves as a quantitative measure of a drug’s safety. A higher therapeutic index indicates a wider "safety window," meaning there is a large margin between the dose required for a desired effect and the dose that causes toxicity or death. Conversely, drugs with a low TI (e.g., Warfarin, Digoxin, Lithium) require frequent plasma monitoring because the toxic dose is very close to the effective dose. **Why other options are incorrect:** * **Bioavailability:** Refers to the fraction of an administered drug that reaches the systemic circulation in an unchanged form. It is calculated via the Area Under the Curve (AUC). * **Potency:** Refers to the amount of drug (dose) required to produce an effect of a given intensity. It is represented by the **EC50** (the concentration producing 50% of the maximum response). * **Efficacy:** Refers to the maximum response ($E_{max}$) a drug can produce, regardless of dose. It is a more clinically important parameter than potency. **High-Yield NEET-PG Pearls:** * **Certain Safety Factor:** A more reliable index than TI, calculated as **LD1 / ED99**. * **Therapeutic Window:** The range of drug dosages which can treat disease effectively without having toxic effects. * **Low TI Drugs (Mnemonic: W-LEAF):** **W**arfarin, **L**ithium, **E**thosuximide, **A**mphotericin B, **F**enytoin (Phenytoin)/Digoxin. These drugs require **Therapeutic Drug Monitoring (TDM)**.

Q: Hepatic first-pass metabolism is important in which route of drug administration?

Drugs taken orally. **Explanation:** **1. Why Option B is Correct:** The **Hepatic First-Pass Effect** (or pre-systemic metabolism) refers to the phenomenon where a drug is metabolized by the liver before it reaches the systemic circulation. When a drug is taken **orally**, it is absorbed from the gastrointestinal tract into the **portal venous system**. This blood flows directly to the liver via the portal vein. Consequently, a significant fraction of the drug may be inactivated by hepatic enzymes (like Cytochrome P450) or excreted into bile, reducing its overall bioavailability. **2. Why Other Options are Incorrect:** * **Option A (Intramuscular):** Drugs administered via the IM route are absorbed directly into the systemic capillaries, bypassing the portal circulation and the liver initially. * **Option C (Intravenous):** IV administration provides 100% bioavailability because the drug is injected directly into the systemic venous return, completely bypassing the GI tract and the first-pass effect of the liver. **3. NEET-PG High-Yield Clinical Pearls:** * **Bioavailability (F):** Drugs with high first-pass metabolism have low oral bioavailability. To achieve the same therapeutic effect, the oral dose must be significantly higher than the IV dose (e.g., **Propranolol**). * **Classic Examples:** Drugs with extensive first-pass metabolism include **Nitroglycerin** (why it is given sublingually), **Lidocaine** (not effective orally for arrhythmias), **Morphine**, and **Salbutamol**. * **Bypassing First-Pass:** Apart from parenteral routes (IV/IM/SC), first-pass metabolism can be bypassed using **sublingual**, **transdermal**, or **rectal** (partially) routes. The upper part of the rectum drains into the portal system, while the lower part drains directly into the systemic circulation.

Q: Which of the following drugs has the maximum chance of absorption from the gastric mucosa?

Diclofenac sodium. ### Explanation The absorption of a drug across biological membranes is primarily governed by its **degree of ionization**, which depends on the drug's pKa and the pH of the surrounding medium. According to the **pH Partition Hypothesis**, only the non-ionized (lipid-soluble) form of a drug can easily cross lipid membranes. **1. Why Diclofenac Sodium is Correct:** Diclofenac is a **weakly acidic drug** (pKa ≈ 4.0). In the highly acidic environment of the stomach (pH 1–2), weak acids remain largely in their **non-ionized, protonated form**. This makes them lipid-soluble and allows for significant absorption directly through the gastric mucosa. **2. Why the Other Options are Incorrect:** * **Morphine sulfate, Hyoscine hydrobromide, and Quinine dihydrochloride** are all **weakly basic drugs**. * In the acidic gastric environment, basic drugs become **highly ionized** (protonated). * Ionized molecules are water-soluble but lipid-insoluble; therefore, they cannot cross the gastric mucosal barrier effectively. These drugs are primarily absorbed later in the alkaline environment of the small intestine. **3. High-Yield Clinical Pearls for NEET-PG:** * **General Rule:** Acidic drugs (e.g., Aspirin, Barbiturates, NSAIDs like Diclofenac) are absorbed better in acidic media (stomach). Basic drugs (e.g., Atropine, Morphine, Amphetamines) are absorbed better in alkaline media (intestine). * **Surface Area Factor:** Despite the chemistry, the **small intestine** remains the major site of absorption for *most* drugs (including weak acids) due to its massive surface area compared to the stomach. * **Ion Trapping:** This principle is used clinically in toxicology. For example, alkalinizing the urine with sodium bicarbonate "traps" acidic drugs like Aspirin in the renal tubules, enhancing their excretion.

Q: Which of the following is FALSE regarding non-competitive antagonism?

The drug needs to be structurally similar to the substrate.. ### Explanation In pharmacology, understanding the distinction between competitive and non-competitive antagonism is high-yield for NEET-PG. **Why Option B is the Correct (False) Statement:** In **non-competitive inhibition**, the antagonist does not compete for the same binding site as the substrate. Instead, it binds to an **allosteric site** (a different location on the enzyme or receptor). Because it does not target the active site, the antagonist **does not need to be structurally similar** to the substrate. Structural similarity is a hallmark of *competitive* inhibition, where the drug "mimics" the substrate to fit into the active site. **Analysis of Other Options:** * **Option A (True):** Non-competitive inhibitors bind to allosteric sites, inducing a conformational change in the enzyme that reduces its catalytic activity. * **Option C (True):** Since the inhibitor and substrate are not competing for the same spot, adding more substrate cannot "wash out" or displace the inhibitor. Therefore, the inhibition is **insurmountable**, and the **Vmax is decreased**. * **Option D (True):** In non-competitive inhibition, the affinity of the remaining functional enzymes for the substrate typically remains unchanged. Therefore, the **Km (Michaelis constant) remains the same**. **High-Yield Clinical Pearls for NEET-PG:** * **Competitive Inhibition:** Km increases, Vmax remains unchanged (e.g., Statins vs. HMG-CoA). * **Non-Competitive Inhibition:** Km remains unchanged, Vmax decreases (e.g., Digoxin acting on Na+/K+ ATPase). * **Irreversible Inhibition:** Often grouped with non-competitive kinetics because Vmax decreases (e.g., Aspirin inhibiting COX, Organophosphates inhibiting AChE). * **Key Graph:** On a Lineweaver-Burk plot, non-competitive inhibitors show lines that intersect on the negative X-axis (same -1/Km).

Q: Dosage of a drug is determined by all of the following factors except?

Half-life. To determine the correct dosage of a drug, we must distinguish between the **Loading Dose** and the **Maintenance Dose**. **Why Half-life is the correct answer:** The **half-life ($t_{1/2}$)** of a drug determines the **dosing interval** (how often the drug is given) and the time required to reach **steady-state concentration**, but it does not directly determine the *amount* (dosage) of the drug itself. Dosage is primarily calculated based on Clearance and Volume of Distribution. **Explanation of Incorrect Options:** * **Volume of Distribution ($V_d$):** This is the primary determinant of the **Loading Dose**. Drugs with a high $V_d$ sequester into tissues, requiring a larger initial dose to achieve the desired target plasma concentration ($LD = V_d \times C_p$). * **Excretion/Clearance:** The rate of drug elimination (Clearance) is the primary determinant of the **Maintenance Dose**. If excretion is impaired (e.g., renal failure), the dose must be reduced to avoid toxicity ($MD = CL \times C_{ss}$). * **Lipid Solubility:** This physicochemical property dictates the $V_d$. Highly lipid-soluble drugs cross biological membranes easily and distribute widely into adipose tissue, necessitating dosage adjustments based on body composition. **NEET-PG High-Yield Pearls:** 1. **Loading Dose** depends on **$V_d$** (Targeting the "tank" size). 2. **Maintenance Dose** depends on **Clearance** (Targeting the "leak" rate). 3. **Steady State** is reached after **4–5 half-lives**, regardless of the dose or frequency, provided the infusion/dosing is constant. 4. **Bioavailability (F):** Must be considered for oral dosing ($LD = \frac{V_d \times C_p}{F}$).

Q: Which of the following is NOT an oxidative type of drug metabolism?

Glucuronidation. **Explanation:** Drug metabolism (biotransformation) is broadly classified into two phases: **Phase I (Non-synthetic)** and **Phase II (Synthetic)** reactions. **Why Glucuronidation is the correct answer:** Glucuronidation is a **Phase II reaction**. Unlike Phase I reactions, which involve the addition or uncovering of a functional group (oxidation, reduction, or hydrolysis), Phase II reactions involve the **conjugation** of a drug or its metabolite with an endogenous substance (like glucuronic acid). Glucuronidation is the most common Phase II reaction and is mediated by the enzyme **UGT (UDP-glucuronosyltransferase)**. **Analysis of Incorrect Options (Phase I Oxidative Reactions):** Phase I oxidative reactions are primarily mediated by the Cytochrome P450 (CYP450) enzyme system. * **A. Deamination:** This involves the removal of an amino group (e.g., metabolism of adrenaline or amphetamines). * **B. N–oxidation:** This involves the addition of oxygen to a nitrogen atom (e.g., metabolism of dapsone). * **C. N–dealkylation:** This involves the removal of an alkyl group from a nitrogen atom (e.g., morphine or caffeine metabolism). **High-Yield Clinical Pearls for NEET-PG:** 1. **Microsomal vs. Non-microsomal:** Most Phase I and Phase II enzymes are microsomal (located in the SER), but **Glucuronidation is the only Phase II reaction** carried out by microsomal enzymes. 2. **Gray Baby Syndrome:** This occurs in neonates due to a deficiency of the glucuronyl transferase enzyme, leading to the accumulation of Chloramphenicol. 3. **Crigler-Najjar/Gilbert Syndrome:** These involve genetic deficiencies in the glucuronidation of bilirubin. 4. **Phase II sequence:** Generally, Phase I precedes Phase II, but some drugs (like Isoniazid) undergo Phase II (Acetylation) before Phase I (Hydrolysis).

Q: Which of the following drugs requires dose adjustment in renal failure?

Streptomycin. **Explanation:** The primary determinant for dose adjustment in renal failure is the drug’s route of elimination. Drugs primarily excreted unchanged by the kidneys require dose reduction to prevent toxicity, whereas those eliminated via the liver (biliary/fecal) generally do not. **Why Streptomycin is Correct:** Streptomycin is an **Aminoglycoside**. Aminoglycosides are highly polar, water-soluble molecules that are excreted almost entirely (90%+) by glomerular filtration in their active form. In renal impairment, their clearance decreases proportionally to the decline in Creatinine Clearance (CrCl), leading to accumulation. This significantly increases the risk of **nephrotoxicity** and **ototoxicity**. Therefore, dose adjustment (either reducing the dose or lengthening the interval) is mandatory. **Why the Other Options are Incorrect:** * **Cefoperazone:** Unlike most cephalosporins, Cefoperazone (and Ceftriaxone) is primarily excreted through the **bile**. It does not require dose adjustment in renal failure but may require it in hepatic impairment. * **Doxycycline:** This is a unique tetracycline eliminated primarily via **fecal excretion** (chelated in the intestines). It is the tetracycline of choice in patients with renal failure. * **Rifampicin:** This is a highly lipid-soluble drug metabolized by the **liver** and excreted mainly through bile. It is safe to use in standard doses in patients with renal insufficiency. **High-Yield Clinical Pearls for NEET-PG:** * **"Safe" drugs in renal failure (No dose adjustment):** Doxycycline, Ceftriaxone, Cefoperazone, Rifampicin, Erythromycin, and Clindamycin. * **Aminoglycoside Rule:** Always monitor "Peak" levels for efficacy and "Trough" levels to minimize toxicity. * **Formula:** For drugs like Streptomycin, the new dose interval can be estimated as: *Normal Interval × (Patient’s Creatinine / Normal Creatinine).*

Question 1

Drugs with high plasma protein binding have:

Accepted Answer

Lower volumes of distribution

Answer

Short duration of action

Answer

Less drug interactions

Answer

All of the above

Question 2

Which of the following inhibits theophylline metabolism?

Accepted Answer

Ciprofloxacin

Answer

Griseofulvin

Answer

Prednisolone

Answer

Isoniazid

Question 3

The maximum effect of a drug is defined by which of the following parameters?

Accepted Answer

Efficacy

Answer

Therapeutic index

Answer

Potency

Answer

Adversity

Question 4

What does the ratio of LD50 to ED50 represent?

Accepted Answer

Therapeutic index

Answer

Bioavailability

Answer

Potency

Answer

Efficacy

Question 5

Hepatic first-pass metabolism is important in which route of drug administration?

Accepted Answer

Drugs taken orally

Answer

Drugs given intramuscularly

Answer

Drugs given intravenously

Answer

None of the above

Question 6

Which of the following drugs has the maximum chance of absorption from the gastric mucosa?

Accepted Answer

Diclofenac sodium

Answer

Morphine sulfate

Answer

Hyoscine hydrobromide

Answer

Quinine dihydrochloride

Question 7

Which of the following is FALSE regarding non-competitive antagonism?

Accepted Answer

The drug needs to be structurally similar to the substrate.

Answer

The drug binds to an allosteric site of the enzyme.

Answer

The inhibition cannot be overcome by increasing the substrate concentration.

Answer

The Km remains the same.

Question 8

Dosage of a drug is determined by all of the following factors except?

Accepted Answer

Half-life

Answer

Volume of distribution

Answer

Lipid solubility

Answer

Excretion of the drug

Question 9

Which of the following is NOT an oxidative type of drug metabolism?

Accepted Answer

Glucuronidation

Answer

Deamination

Answer

N–oxidation

Answer

N–dealkylation

Question 10

Which of the following drugs requires dose adjustment in renal failure?

Accepted Answer

Streptomycin

Answer

Cefoperazone

Answer

Doxycycline

Answer

Rifampicin

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?